Arul M. Chinnaiyan, M.D., Ph.D. is the Director of the Michigan Center for Translational Pathology, the S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan, and an Investigator of the Howard Hughes Medical Institute. He is a member of the American Academy of Arts and Sciences and the National Academies of Science and Medicine. Dr. Chinnaiyan is best known for the discovery of TMPRSS2-ETS gene fusions in a majority of prostate cancers, the first causative gene fusion identified in a common solid tumor. Recurrent gene fusions have since been characterized as targetable driver alterations across subsets of carcinomas. In 2010, Dr. Chinnaiyan’s group established the first comprehensive clinical sequencing approach for advanced cancer patients called MI-Oncoseq, which has served as a paradigm for cancer precision medicine. He has received a number of awards for his work and most recently received the 2022 Sjöberg Prize for cancer research by the Royal Swedish Academy of Sciences. He has co-authored over 600 manuscripts and mentored numerous trainees who have had successful careers in academia and industry. Dr. Chinnaiyan has co-founded several companies including Armune Biosciences (acquired by Exact Sciences), Compendia Biosciences (acquired by ThermoFisher), Oncopia Therapeutics (acquired by Roivant), Esanik Therapeutics, Flamingo Therapeutics, MedsynBio and LynxDx.